A Phase II, Randomized Double-blind, 2-part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa™) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-small Cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment With ZD1839.
CompletadoFase 2ClinicalTrials.gov
ID: NCT00059722Tipo: INTERVENTIONALInicio: 1 de may de 2003Fin estimado: 1 de jun de 2007
The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
Elegibilidad
Edad mínima: 18 YearsSexo: ALL
Criterios de inclusión
Failure of either first-line and/or second-line chemotherapy either of which was platinum-based (the prior regimen must have failed the subject because of toxicity or progression of tumor
Prior histologic or cytologic confirmation of locally advanced or metastatic (IIIB/IV) NSCLC
Criterios de exclusión
Subjects who have received second-line or subsequent chemotherapy
Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic, need not be excluded)
Intervenciones
drug
ZD6474
drug
Placebo
drug
ZD1839
Ubicaciones
Research Site
Buenos Aires, Argentina
Research Site
Mendoza, Argentina
Patrocinadores
PrincipalGenzyme, a Sanofi Company
Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.
A Phase II, Randomized Double-blind, 2-part, Multicenter ... | EligiMed